MLA Diagnostics

A revolutionary prognostic test for early stage melanoma


Melanoma is the most deadly form of skin cancer. After diagnosis it is vital to know the risk of whether the disease is likely to spread. Prognostic information is important at this stage. Unfortunately current prognostic tools often classify patients as low risk but these patients still progress to metastatic disease and die without getting the treatment they needed.


MLA Diagnostics’ innovative product is an in vitro diagnostic (IVD) method that is able to determine melanoma patients with low or high metastatic risk. Performed by the pathologist, this test provides more insight on a patients’ expected outcome and will enable a different course of treatment (more or less intensive).

News from MLA Diagnostics

MIT Haalbaarheid subsidy received

The Mkb-innovatiestimulering Regio en Topsectoren (MIT) stimulates innovation in SMEs to align project with the top sectors. MLA Diagnostics received funding for a feasibility project

Read More →

Contact Us

Visit us in Maastricht

Where research and entrepreneurship come together